Greetings, Skipta Community:
We have summarized the following peer-reviewed journal article for your consideration. We welcome your feedback.
TITLE: Real-world utilization of biomarker testing for patients with advanced non–small cell lung cancer in a tertiary referral center and referring hospitals
SUMMARY: Biomarker testing to...
Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33816221/
We report about SCCT that occurred 45 months after the initial diagnosis of ADC in an East Asian never-smoker woman with advanced-stage EGFR Del-19-mutant lung ADC treated with combined chemoradiotherapy...
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33743408/
Non─small cell lung cancer (NSCLC) presents different druggable genetic abnormalities, including ROS1 and ALK rearrangements, which share relevant clinical features and therapeutic strategies. The homology between the tyrosine kinase domains...
Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33806299/
The potent, RET-selective tyrosine kinase inhibitors (TKIs) pralsetinib and selpercatinib, are effective against the RET V804L/M gatekeeper mutants, however, adaptive mutations that cause resistance at the solvent front RET G810...